Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis

Abstract

Consistent results across all the analyses support the noninferior efficacy of three all-oral shortened regimens for the treatment of rifampin-resistant tuberculosis. (Funded by Unitaid and others; endTB ClinicalTrials.gov number, NCT02754765.).